Skip to main content

Table 3 Comparison of glucose control parameters, insulin secretion and sensitivity surrogates before and after treatment in both groups

From: Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose

  Acarbose (n = 28) Glibenclamide (n = 23)
  Before After P-values vs. baseline Before After P-values vs. baseline
BMI (kg/m2) 25.9 ± 3.0 25.5 ± 3.3 0.005* 25.3 ± 3.8 25.5 ± 4.0 0.072
Fasting plasma glucose (mmol/l) 8.2 ± 1.2 7.3 ± 1.2 0.002* 9.0 ± 3.0 7.2 ± 2.1 0.001*
HbA1c (%) 8.2 ± 0.8 7.5 ± 0.8 <0.001* 8.6 ± 1.6 7.4 ± 1.2 <0.001*
HOMA-IR 3.0 ± 1.4 3.1 ± 2.9 0.682 4.8 ± 3.9 3.5 ± 2.7 0.101
HOMA-β (%) 40.3 ± 30.0 49.4 ± 40.2 0.021* 53.7 ± 50.5 47.0 ± 83.4 0.153
Insulinogenic index30 (pmol/mmol) 47.9 ± 79.0 50.6 ± 42.0 0.080 35.0 ± 37.2 36.1 ± 24.5 0.191
MISI 3.6 ± 1.8 4.6 ± 2.8 0.124 3.2 ± 1.7 4.1 ± 2.9 0.176
AUCins120/AUCglu 120§(pmol/mmol) 2.9 ± 2.3 3.8 ± 3.1 0.003* 2.7 ± 1.4 3.3 ± 1.7 0.121
DI120 62.5 ± 31.4 91.7 ± 36.2 0.002* 51.2 ± 24.2 74.9 ± 41.9 0.003*
  1. Wilcoxon signed rank test; Data are presented as mean ± standard deviation. *P <0.05: § total area under curve of insulin within 120 minutes divided by total area under curve of glucose within 120 minutes.
  2. DI, disposition index; HOMA-β, homeostasis model assessment β-cell function index; HOMA-IR, homeostasis model assesment insulin resistance index; MISI, Matsuda insulin sensitivity index.